BRCA2/ATM carriers were found to have more aggressive features of PrCa at diagnosis: Gleason score 8–10 (88.9% vs 59.5%), metastatic disease at diagnosis (80% vs 52.2%) and higher median PSA at diagnosis (59.0 vs 38.4). This evidence concerns the gene ATM and metastatic neoplasm.